Perceptive Advisors LLC has recently announced that it has increased stake in VBI Vaccines Inc. (NASDAQ:VBIV) by 19.78%. After grabbing 55.04 million shares, the institutional investor is now in possession of 9.09 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 23.86% having worth around $224.02 million. Moreover, BlackRock Fund Advisors increased its share by 1.14 million to have a control over 11.92 million shares. And The Vanguard Group, Inc. raised its holdings to 2.78 million shares by acquiring 5.64 million shares or 2.45% of the stake.
VBI Vaccines Inc. (VBIV) concluded trading on 08/27/20 at a closing price of $4.24, with 197.98 million shares of worth about $839.45 million changed hands on the day. Weekly performance of the stock remained positive as price took a surge of 8.85% during that period and on Thursday the price saw a gain of about 32.24%. Currently the company’s common shares owned by public are about 231.20M shares, out of which, 150.88M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 4 analysts are covering the VBIV stock and their offered price forecasts bring an average price target of $6.75. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $9.00 and could fall to a lowest price of $3.00. Analysts also issued an outlook of 1.50 for the VBI Vaccines Inc. stock for next 12 months. However, touching the estimated high of $9.00 would mean a gain of 52.89% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 5 times over the past 12 months. They bought 29,295,409 shares in 5 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
iShares Russell 2000 ETF, Vanguard Extended Market Index Fu, and iShares Russell 2000 Growth ETF are the top 3 mutual funds which are holding stakes in VBI Vaccines Inc. iShares Russell 2000 ETF is currently holding 3.53 million shares of worth totaling $14.38 million. The company recently came selling -0.17 million shares which brought its stake up to 1.53% of the company’s outstanding shares. Vanguard Extended Market Index Fu sold 6729.0 shares, after which its hold over company’s outstanding shares shrunk to 1.41%, leaving 3.25 million shares with the mutual fund that have a worth of about $13.24 million. iShares Russell 2000 Growth ETF, after selling 1.32 million shares, have now control over 0.57% of the stake in the company. It holds 12952.0 shares of worth $5.36 million.
VBI Vaccines Inc. (NASDAQ: VBIV) started trading at $4.15, above $0.94 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $4.24, or with a gain of 32.24%. Stock saw a price change of 8.85% in past 5 days and over the past one month there was a price change of 11.71%. Year-to-date (YTD), VBIV shares are showing a performance of 207.61% which increased to 563.28% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.47 but also hit the highest price of $6.93 during that period. While comparing its average daily trading volume of 12.58 million shares, we see that about 197.98 million changed hands on the day. The stock is currently trading 9.04% above its 20-day simple moving average (SMA20), while that difference is up 8.99% for SMA50 and it goes to 115.86% higher than SMA200.
Perceptive Advisors LLC acquired 55.04 million shares of VBI Vaccines Inc. having value of about $224.02 million. Data submitted at the U.S SEC by Perceptive Advisors LLC revealed that the firm now holds 9.09 million shares in the company valued at close to $38545416.0, or have control over 19.78% stake in the company. VBI Vaccines Inc. (NASDAQ: VBIV) currently have 231.20M outstanding shares and institutions hold larger chunk of about 44.45% of that. Holding of mutual funds in the company is about 35.30% while other institutional holders and individual stake holders have control over 8.96% and 30.56% of the stake respectively.
The stock has a current market capitalization of $981.44M. It has posted earnings per share of -$0.27 in the same period. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VBIV, volatility over the week remained 16.14% while standing at 13.00% over the month.
Analysts are in expectations that VBI Vaccines Inc. (VBIV) stock would likely to be making an EPS of -$0.22 in the current quarter, while forecast for next quarter ESPS is -$0.21 and it is -$0.77 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.22 which is -$0.22 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.24 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by 0.00% while it is estimated to increase by 12.50% in next year.
Analysts at 4 brokerage firms have issued recommendations for the VBI Vaccines Inc. (VBIV)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.50. Out of those 4 Wall Street analysts, 4 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on August 27, 2020 offering a Strong buy rating for the stock and assigned a target price range of between $8 and $9 to it. Coverage by Oppenheimer stated VBI Vaccines Inc. (VBIV) stock as an Outperform in their note to investors on January 16, 2019, suggesting a price target of $9 for the stock. On November 01, 2017, Canaccord Genuity Initiated their recommendations, while on October 10, 2016, Laidlaw Initiated their ratings for the stock with a price target of $6. Stock get a Buy rating from Ladenburg Thalmann on July 26, 2016.